Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Trey Thoelcke | Jun 5, 2014 at 10:20 AM EDT

Four Top Medical Device Stocks That Are Takeover Candidates

Here are four top medical device makers that the Leerink team thinks make sense as potential takeover candidates, but also…

Jon C. Ogg | Jun 4, 2014 at 9:50 AM EDT

UnitedHealth Delivers Healthy Dividend Hike and Major Stock Buyback Plan

UnitedHealth Group must be doing OK. The largest health insurer has announced a dividend hike and a new share buyback…

Trey Thoelcke | Jun 3, 2014 at 8:45 AM EDT

Top Biotech Stocks to Buy According to Portfolio Managers

A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as…

Jon C. Ogg | Jun 2, 2014 at 8:55 AM EDT

Analyst Cancer and Biotech Stock Picks From ASCO

ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty…

Paul Ausick | May 30, 2014 at 3:05 PM EDT

Valeant Offers Even More for Botox-Maker Allergan

ThinkstockCanada-based Valeant Pharmaceuticals Inc. (NYSE: VRX) has raised its offer for Allergan Inc. (NYSE: AGN) for the second time this…

Trey Thoelcke | May 30, 2014 at 9:05 AM EDT

Analyst Stocks to Buy for an Aging America

ThinkstockThe United States is not alone as our population ages. We join Japan and several other developed nations with a…

Jon C. Ogg | May 27, 2014 at 1:35 PM EDT

Pfizer’s Real Issue: Identity Crisis Against Peers

Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance…

Paul Ausick | May 27, 2014 at 10:50 AM EDT

BioCryst Crushes It on Rare Immune Disorder Drug Trial

BioCryst Pharmaceuticals broke higher Tuesday morning, following the company's announcement that its oral drug for hereditary angioedema met objectives established…

Trey Thoelcke | May 22, 2014 at 8:40 AM EDT

Three Companies That Want to Cure Pancreatic Cancer

A new research report from Cowen cautions that progress on a cure for pancreatic cancer is slow, but steady. Drugs…

Trey Thoelcke | May 22, 2014 at 8:20 AM EDT

Why You Buy Big Pharma If the Market Crashes

A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is…

Jon C. Ogg | May 16, 2014 at 8:30 AM EDT

Top Biotech Stocks for Cancer Cures From Cowen

ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance…

Trey Thoelcke | May 15, 2014 at 8:20 AM EDT

Three Oversold Biotech Stocks That Could Have Gigantic Upside

ThinkstockThe biotech meltdown that started in late February was an indiscriminate killer. The top mega-cap sector leaders were shot down…

Jon C. Ogg | May 12, 2014 at 12:35 PM EDT

Should Allergan Shareholders Be Worried?

Allergan has been a great company, and it can still be one in the future. The question is whether this…

Jon C. Ogg | May 8, 2014 at 3:03 PM EDT

Will the Last Interested Person in Dendreon Turn Out the Lights?

Dendreon is getting crushed, and the share price is down to levels not seen in a decade. The company's reported…

Paul Ausick | May 6, 2014 at 11:05 AM EDT

Cross-Border Premium Implications in Merck-Bayer Transaction

Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced…

1 … 286 287 288 289 290 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Four Top Medical Device Stocks That Are Takeover Candidates

UnitedHealth Delivers Healthy Dividend Hike and Major Stock Buyback Plan

Top Biotech Stocks to Buy According to Portfolio Managers

Analyst Cancer and Biotech Stock Picks From ASCO

Valeant Offers Even More for Botox-Maker Allergan

Analyst Stocks to Buy for an Aging America

Pfizer’s Real Issue: Identity Crisis Against Peers

BioCryst Crushes It on Rare Immune Disorder Drug Trial

Three Companies That Want to Cure Pancreatic Cancer

Why You Buy Big Pharma If the Market Crashes

Top Biotech Stocks for Cancer Cures From Cowen

Three Oversold Biotech Stocks That Could Have Gigantic Upside

Should Allergan Shareholders Be Worried?

Will the Last Interested Person in Dendreon Turn Out the Lights?

Cross-Border Premium Implications in Merck-Bayer Transaction

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

Health and Healthcare Articles

All Health and Healthcare Articles

Four Top Medical Device Stocks That Are Takeover Candidates

UnitedHealth Delivers Healthy Dividend Hike and Major Stock Buyback Plan

Top Biotech Stocks to Buy According to Portfolio Managers

Analyst Cancer and Biotech Stock Picks From ASCO

Valeant Offers Even More for Botox-Maker Allergan

Analyst Stocks to Buy for an Aging America

Pfizer’s Real Issue: Identity Crisis Against Peers

BioCryst Crushes It on Rare Immune Disorder Drug Trial

Three Companies That Want to Cure Pancreatic Cancer

Why You Buy Big Pharma If the Market Crashes

Top Biotech Stocks for Cancer Cures From Cowen

Three Oversold Biotech Stocks That Could Have Gigantic Upside

Should Allergan Shareholders Be Worried?

Will the Last Interested Person in Dendreon Turn Out the Lights?

Cross-Border Premium Implications in Merck-Bayer Transaction

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

Featured Reads

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds